文献速递神经核医学

验证123I-FP-CIT SPECT定量方法在路易体痴呆及其他神经退行性疾病中的应用

Confirmation of 123I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders.
PubMed 文献 · J Nucl Med · 2020-03-20

该回顾性研究以神经病理学为参考标准,在24例神经退行性综合征患者中比较MIMneuro、DaTQUANT和手动感兴趣区三种123I-FP-CIT SPECT定量方法,发现三种方法在各评估脑区对路易体病与非路易体病患者均表现出极好的鉴别能力(AUC>0.93至1.000,P<0.001),各脑区准确率间无显著差异。

要点

  • 三种123I-FP-CIT SPECT定量方法(MIMneuro、DaTQUANT、手动ROI)均以神经病理学为参考标准进行验证。
  • 所有方法在各评估脑区对路易体病与非路易体病的鉴别AUC均>0.93至1.000(P<0.001)。
  • 尾状核与壳核均显示良好鉴别能力,各脑区间准确率无显著差异。

核心结论

  • 三种123I-FP-CIT SPECT定量方法使用纹状体-背景比值和z分数,在各评估脑区对路易体病与非路易体病患者均表现出极好的鉴别能力。

研究设计与样本

  • 回顾性研究,纳入来自Mayo阿尔茨海默病研究中心和Mayo Clinic Study of Aging的24例神经退行性综合征患者,比较三种123I-FP-CIT SPECT定量方法与神经病理学所见的路易体病存在与否。

主要发现

  • 队列包括24例患者(20例[83%]男性,所有患者死亡时平均年龄75.4±10.0岁)。
  • 17例(71%)有路易体病。
  • 所有三种123I-FP-CIT SPECT定量方法的受试者工作特征曲线下面积范围为大于0.93至1.000(P<0.001),在每个评估脑区均显示对路易体病与非路易体病患者的极好鉴别(P<0.001)。
  • 各脑区在鉴别两组间的准确率无显著差异,尾状核和壳核均显示良好鉴别能力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our rationale was to conduct a retrospective study comparing 3 123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (123I-FP-CIT) SPECT quantitative methods in patients with neurodegenerative syndromes as referenced to neuropathologic findings. Methods:123I-FP-CIT-SPECT and neuropathologic findings among patients with neurodegenerative syndromes from the Mayo Alzheimer Disease Research Center and Mayo Clinic Study of Aging were examined. Three 123I-FP-CIT SPECT quantitative assessment methods-MIMneuro, DaTQUANT, and manual region-of-interest creation on a workstation-were compared with neuropathologic findings describing the presence or absence of Lewy body disease (LBD). Striatum-to-background ratios (SBRs) generated by DaTQUANT were compared with the calculated SBRs of the manual method and MIMneuro. The left and right SBRs for caudate, putamen, and striatum were evaluated with the manual method. For DaTQUANT and MIMneuro, the left, right, total, and average SBRs and z scores for whole striatum, caudate, putamen, anterior putamen, and posterior putamen were calculated. Results: The cohort included 24 patients (20 [83%] male, mean age for all patients at death, 75.4 ± 10.0 y). The antemortem clinical diagnoses were Alzheimer disease dementia (n = 6), probable dementia with Lewy bodies (n = 12), mixed Alzheimer disease dementia and probable dementia with Lewy bodies (n = 1), Parkinson disease with mild cognitive impairment (n = 2), corticobasal syndrome (n = 1), idiopathic rapid-eye-movement sleep behavior disorder (n = 1), and behavioral-variant frontotemporal dementia (n = 1). Seventeen (71%) had LBD. All 3 123I-FP-CIT SPECT quantitative methods had an area under the receiver-operating-characteristics curve ranging from more than 0.93 to up to 1.000 (P < 0.001) and showed excellent discrimination between LBD and non-LBD patients in each region assessed (P < 0.001). There was no significant difference between the accuracy of the regions in discriminating the 2 groups, with good discrimination for both caudate and putamen. Conclusion: All 3 123I-FP-CIT SPECT quantitative methods showed excellent discrimination between LBD and non-LBD patients in each region assessed, using both SBRs and z scores.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Maltais DD, Jordan LG, Min HK, et al. Confirmation of 123I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders. J Nucl Med. 2020. PMID: 32198310. doi:10.2967/jnumed.119.239418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。